1-(2-Hydroxy-phenyl)-3-methyl-butan-2-one | 117379-93-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 1-(2-Hydroxy-phenyl)-3-methyl-butan-2-one
• 英文别名: 1-(2-Hydroxyphenyl)-3-methylbutan-2-one
• CAS: 117379-93-8
• 化学式: C₁₁H₁₄O₂
• 分子量: 178.231
• InChiKey: BBRNYRRDHCWQTF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(2-Hydroxy-phenyl)-3-methyl-butan-2-one 、 无水氯化铬(Ⅱ) 、 四氢呋喃 、 溶剂黄146 、 盐酸 以100%的产率得到
  参考文献：
  名称：

  LEDOUSSAL, B.;GORGUES, A.;LE, COQ A., TETRAHEDRON, 43,(1987) N 24, 5841-5852

  摘要：

  DOI：
• 作为产物：
  描述：

  1-(2-Methoxy-phenyl)-3-methyl-butan-2-one 在 三甲基氯硅烷 、 sodium iodide 作用下， 生成 1-(2-Hydroxy-phenyl)-3-methyl-butan-2-one
  参考文献：
  名称：

  邻碘苯甲醚的S RN 1反应新合成苯并[ b ]呋喃

  摘要：

  从邻-碘苯甲醚开始，可通过芳族亲核基团取代（S RN 1）以高收率获得2-取代的苯并[ b ]呋喃。

  DOI：

  10.1039/c39800000508

文献信息

• [EN] MACROCYCLIC COMPOUNDS FOR MODULATING IL-17<br/>[FR] COMPOSÉS MACROCYCLIQUES POUR UNE MODULATION D'IL-17
  申请人：ENSEMBLE THERAPEUTICS CORP

  公开号：WO2013116682A1

  公开（公告）日：2013-08-08

  The invention relates generally to macrocyclic compounds of formula I and their therapeutic use. More particularly, the invention relates to macrocyclic compounds that modulate the activity of IL-17 and/or are useful in the treatment of medical conditions, such as inflammatory diseases and other IL-17-associated disorders.

  这项发明通常涉及公式I的大环化合物及其治疗用途。更具体地，该发明涉及调节IL-17活性的大环化合物，或者用于治疗炎症性疾病和其他与IL-17相关的疾病的大环化合物。
• Reduction par les sels chromeux de bromures benzyliques ortho-o-acyles avec transposition du groupement acyle
  作者：B. Ledoussal、A. Gorgues、A. Le Coq

  DOI：10.1016/s0040-4020(01)87790-5

  日期：——

  σ-bonded organochromium (III) complexes resulting from the reduction of-O-acyl benzylic bromides with CrCl2., undergo an 1,5-transposition of the ester acyl functional group which allows, through selected experimental conditions either a selective access to the unmasked -hydroxybenl ketones or a new preparation of the 2-substituted benzo¦b¦furans . The scope and limitations of the method are presented

  由-O-酰基苄基溴化物经CrCl 2还原而形成的σ键合有机铬（III）配合物经历了酯酰基官能团的1,5-转移，这允许通过选择的实验条件或者选择性地获得非掩蔽的羟基苯甲酮或2-取代的苯并γ-b呋喃的新制备方法。介绍了该方法的范围和局限性。
• MACROCYCLIC COMPOUNDS FOR MODULATING IL-17
  申请人：ENSEMBLE THERAPEUTICS CORPORATION

  公开号：US20150005319A1

  公开（公告）日：2015-01-01

  The invention relates generally to macrocyclic compounds of formula I and their therapeutic use. More particularly, the invention relates to macrocyclic compounds that modulate the activity of IL-17 and/or are useful in the treatment of medical conditions, such as inflammatory diseases and other IL-17-associated disorders.

  本发明涉及公式I的大环化合物及其治疗用途。更具体地，本发明涉及调节IL-17活性或用于治疗医疗情况（例如炎症性疾病和其他IL-17相关疾病）的大环化合物。
• OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS
  申请人：Sun Ying

  公开号：US20080292587A1

  公开（公告）日：2008-11-27

  The present invention discloses compounds of formulae I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：SNU R&DB FOUNDATION

  公开号：US20160340331A1

  公开（公告）日：2016-11-24

  A compound inhibiting Hsp90 and a pharmaceutical composition including the same as an active ingredient are described, which compound is represented by formula 2 and suppresses the expression of Hsp90, inhibits the accumulation of HIF-1α, the Hsp90 client protein, and efficiently inhibits the activation of VEGF. The compound displays low cytotoxicity and can be effectively used as an active ingredient of an anti-cancer agent, a diabetic retinopathy treating agent, and an anti-arthritic agent.